

B1 concd.
Preferably the fusion partner is protein D or its' lipidated derivative Lipoprotein D, from Haemophilus influenzae B. In particular, it is preferred that the N-terminal

In the claims:

Please amend claims 32-38 and 54 as follows:

Sub.C1

32. An immunogenic composition which comprises a protein comprising

- (a) an HIV Tat protein or an immunogenic derivative linked to an HIV Nef protein or an immunogenic derivative thereof; or
- (b) an HIV Nef protein or an immunogenic derivative linked to an HIV Tat protein or an immunogenic derivative thereof; or
- (c) an HIV Nef protein or an immunogenic derivative linked to an HIV Tat protein or an immunogenic derivative thereof and a fusion partner, in admixture with a pharmaceutically acceptable excipient.

B2

33. A composition as claimed in claim 32, comprising a Tat-Nef fusion protein or an immunogenic derivative thereof.

34. A composition as claimed in claim 32, comprising a Nef-Tat fusion protein or an immunogenic derivative thereof.

35. A composition according to claim 32, wherein the derivative of the Tat protein is an immunogenic mutated Tat protein.

36. A composition according to claim 32, wherein the derivative of the Nef protein is an immunogenic mutated Nef protein.

37. A composition as claimed in claim 32, wherein the fusion partner is a lipoprotein or an immunogenic derivative thereof.

38. A composition as claimed in claim 37, wherein the lipoprotein is Haemophilus Influenza B protein D or an immunogenic derivative thereof.